3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Recruiting
3
Completed
3
Unknown
2
Terminated
2
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
2
OTHER_GOV
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
137
Breast
69
Head & Neck
14
Other solid neoplasm
9
Tumor-Agnostic
6
CNS
6
NET
3
Gynecologic
3
Endocrine
3
Thoracic
2
Genitourinary
2
Other neoplasm
1
Dermatologic
1
Conditions
Neuroendocrine Tumors
3
Interventions
lutetium Lu 177 dotatate
15
Magnetic Resonance Spectroscopy
9
Everolimus
8
gallium Ga 68 dotatate
6
lanreotide
4
cabozantinib
4
Temozolomide
4
Specimen Handling
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
surufatinib
3
olaparib
3
copper dotatate CU-64
3
Somatostatin
3
Injections
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Capecitabine
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Sunitinib
2
Radiosurgery
2
Octreotide
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Capecitabine
×
NET
×
Clear all
NCT04339036
2025-12-10
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
70 enrolled
NCT07185672
2025-09-22
PReCedeNT
Tata Memorial Hospital
Phase 3
Recruiting
162 enrolled
NCT05387603
2025-09-10
START-NET
Lund University Hospital
Phase 3
Recruiting
300 enrolled